

Special Issue

Biomarkers in Chronic Kidney Disease

Message from the Guest Editors

In the evaluation of the real impact of medicines along the wide spectrum of chronic kidney disease (CKD), authentic treatment-effect modifiers, i.e., markers of the effect of medicines, and independent prognostic factors, i.e., markers of the likely progress of a disease regardless of the treatment given, are urgently needed in order to personalize therapies in this population. Also known as a predictive biomarker, the status of treatment effect modifiers changes in accordance with the effect of a given medicine, so it may be used to discern between good and poor responders. This Special Issue on Biomarkers in Chronic Kidney Disease is thus aimed as a compilation of original research articles and review articles on potential candidates to predictive and prognostic biomarkers in this susceptible population.

Guest Editors

Prof. Dr. Francisco Herrera-Gómez

1. Kidney Resuscitation and Acute Purification Therapies, Sanidad de Castilla y León and University of Valladolid, Zamora and Valladolid, Spain
2. Transplantation Center, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

Prof. Dr. F. Javier Álvarez

Pharmacological Big Data Laboratory, Faculty of Medicine, University of Valladolid, 47005 Valladolid, Spain

Deadline for manuscript submissions

closed (30 April 2021)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/43046

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).